Integrating the knowledge of cellular immunology, regulatory biology, molecular biology and peptide chemistry and protein scaffold technology, we design innovative new generation of anti-allergy drug with high efficacies and large safety margin. The treatment leads to low levels of IgE and prevent activation of IgE sensitized mast cells. The second generation of IgE therapeutics aims at altering the natural course of allergic asthma.